Con: On cardiovascular outcomes and the arteriovenous fistula: lesser of evils

2005; 29: 960–964 46. Dixon BS, Noval L, Fangman J. Hemodialysis vascular access survival: upper-arm native arteriovenous fistula. Am J Kidney Dis 2002; 39: 92–101 47. Tordoir J, Canaud B, Haage P et al. EBPG on vascular access. Nephrol Dial Transplant 2007; 22 (Suppl 2): ii88–ii117 48. Amerling R, Ronco C, Kuhlmann M et al. Arteriovenous fistula toxicity. Blood Purif 2011; 31: 113–120 49. Basile C, Lomonte C, Konner K. The arteriovenous fistula: lesser evil or God’s blessing? Blood Purif 2011; 32: 253 50. Vanholder R, Massy Z, Argilés A et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048–1056 51. Muntner P, He J, Hamm L et al. Renal Insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 15: 745–753 52. Stenvinkel P, Amann K, Ketteler M. Cardiovascular disease in chronic kidney disease.In: Feehally J, Floege J, Johnson RJ (eds). Comprehensive Clinical Nephrology. Philadelphia, PA: Mosby, Inc., 2007, pp. 839–852 53. Shinohara K, Shoji T, Tsujimoto Y et al. Arterial stiffness in predialysis patients with uremia. Kidney Int 2004; 65: 936–943 54. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1995; 7: 1277–1285 55. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782–1789 56. Dinwiddie L. “Eligibility” is key word in Fistula First Breakthrough Initiative in determining fistula use. Nephrol News Issues 2006; 20: 39–40 57. Lomonte C, Basile C. The role of the nephrologist in the management of vascular access. Nephrol Dial Transplant 2011; 26: 1461–1463